Category Archive: science communication

Nov
10

Pros and Cons of Social Networking for Scientists: Its not just about Me

I have Antony Williams to thank because for a long time I have been wanting to summarize my thoughts on how I use social networking to spread the word about the science that I am involved in. Seeing Tony’s slides pushed me to do this! This follows visiting many groups of students (most recently at …

Continue reading »

Oct
27

Learning from pioneers in science from the 20th Century

Having just completed review of a manuscript that profiled a prominent scientist in my field from the 20th century, it got me thinking openly. Firstly, I rarely read profiles of long deceased scientists in my field, frankly who but perhaps the odd emeritus professor (with all due respect) would have time on their hands to …

Continue reading »

Oct
19

Old drug, no news: deceased Chemist on front page of Wall Street Journal

Albert Hofmann passed away in 2008 but today he made it to the front page of the Wall Street Journal (WSJ), surrounded by articles on Syria, Wal-Mart, the Canadian election and megadeals. I am still trying to figure out why the location of the old papers and notebooks of this chemist was newsworthy. Could it …

Continue reading »

Oct
05

Nobel prize in medicine – going back to natural products for drugs

Every year there are potentially 1000’s of scientists that could have won the Nobel prize and did not. This year the prize recognizes 3 scientists for their work on parasitic diseases.  William Campbell  and Satoshi Omura won for their work on discovering Avermectin which lead to treatments for River Blindness and Lymphatic Filariasis. Youyou Tu …

Continue reading »

Sep
22

A case for cheaper drug discovery and development

The news has been covering biotech/ pharma for the last few days and it is not a good thing, all because of Turing Pharmaceuticals decision to hike the price of their drug 5000%, which is an old antimalarial called pyrimethamine.  Not surprising the decision was met with an outcry. But looking at the basis for …

Continue reading »

Sep
11

C&EN’s Advances in Drug Discovery and Development

Next Thursday at 10am EST I will be giving a virtual seminar at this virtual symposium – you can find out more and see all the other speakers too. This is a first for me – So I hope for some interaction via Twitter #CENSYM15 Slides are done, now I just have to prepare what …

Continue reading »

Jul
16

What’s needed for TB: A critical analysis of the drug discovery pipeline and efforts

After attending the Gordon conference on Tuberculosis (TB) drug discovery (without breaking the rules on describing what was presented) I think I can safely make a few general comments which were already in my mind before the meeting. This week what stood out for me was the lack of knowledge of all the efforts that …

Continue reading »

May
28

Turning points and games with a purpose

Today I was talking to one of my old mentors from my postdoc days (in big pharma), for the first time in a few years. I realized that working with him and exposure to computational chemistry software  was a real turning point in my career in 1996. Several more turning points later …and I am …

Continue reading »

May
26

A triple life in science

Ever since embarking on my pretty unusual career path in leaving big pharma in 2001, I have been faced with several forks in the road, hard decisions on which way to go. To join a software company or not? work with university spin out? – some were good decisions others less so. Since 2008 I …

Continue reading »

May
20

My experiences reviewing at PLOS

While I am a supporter and proponent of open accessing publishing, I have in the past been fairly critical of some of these journals, in particular PLOS. Even though I still publish in their journals I have held off from PLOS ONE in favor of F1000Research who I feel have a better publishing – reviewing …

Continue reading »

Older posts «

» Newer posts